middle.news
Imugene’s Azer-cel Hits 100% Response in CLL/SLL and Raises $16M for Trial Expansion
11:54am on Thursday 30th of April, 2026 AEST
•
Healthcare
Read Story
Imugene’s Azer-cel Hits 100% Response in CLL/SLL and Raises $16M for Trial Expansion
11:54am on Thursday 30th of April, 2026 AEST
Key Points
100% overall response rate in CLL/SLL patients
80% response rate in Marginal Zone Lymphoma
Phase 1b trial adds BTKi combination arm and Mantle Cell Lymphoma
$16 million raised via placement and SPP
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imugene (ASX:IMU)
OPEN ARTICLE